Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose

Clinical Toxicology

Volumn 52, Issue 4, 2014, Pages 283-287

  Chiew, A L ^a,b   Khamoudes, D ^a   Chan, B S H ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Overdose; Poisoning; Renal replacement therapy; Thrombin inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ADRENALIN; AMLODIPINE; CALCIUM; CREATININE; DABIGATRAN ETEXILATE; HEPARIN; INSULIN; METARAMINOL; METOPROLOL; MOXONIDINE; NORADRENALIN; OLMESARTAN; PROTHROMBIN COMPLEX; PROTHROMBINEX; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD FLOW VELOCITY; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG OVERDOSE; FILTER; HEMODIALYSIS MACHINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAVASCULAR CATHETER; LOADING DRUG DOSE; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMA CLEARANCE; POLYPHARMACY; RESUSCITATION; SUICIDE ATTEMPT; THROMBIN TIME; ULTRAFILTRATION;

AGED; ANTITHROMBINS; BENZIMIDAZOLES; DRUG OVERDOSE; HEMODIAFILTRATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; POLYPHARMACY; PYRIDINES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899087045     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2014.900179     Document Type: Article

References (14)

1. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2011; 103:1116-1127.
2. Biomed H. Hemoclot Thrombin Inhibitors Product Information. Avaliable at: http://www.aniara.com/pdf/, 2011. Accessed 16th September 2013.
3. Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, et al. The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. Clin Toxicol (Phila) 2012; 50:403-413.
4. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011; 7:281-287.
5. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285-295. (Pubitemid 351508116)
6. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386-399. (Pubitemid 351185753)
7. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013; 61:487-489.
8. Pradaxa (dabigatran extexilate) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2010.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139-1151.
10. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259-268.
11. Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 8:1533-1539.
12. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107:985-997.
13. Gibson TP. Problems in designing hemodialysis drug studies. Pharmacotherapy 1985; 5:23-29. (Pubitemid 15140502)
14. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109:596-605.